Dexmedetomidine for end of life sedation: retrospective cohort comparison study.

Benjamin ThomasGregory BarclayMichael Barbato

Published in: BMJ supportive & palliative care (2023)

This study demonstrates a reduction in breakthrough medication requirements, particularly benzodiazepines, for patients sedated with dexmedetomidine at end of life.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
cardiac surgery
chronic kidney disease
prognostic factors
emergency department
cross sectional
mechanical ventilation
acute respiratory distress syndrome